


PRODUCT INFORMATION



Fantofarone

Item No. 26381

CAS Registry No.: 114432-13-2
Formal Name: 3,4-dimethoxy-N-methyl-N-[3-[4-[[2-(1-methylethyl)-1-indoliziny]sulfonyl]phenoxy]propyl]-benzeneethanamine
Synonym: SR 33557
MF: C₃₁H₃₈N₂O₅S
FW: 550.7
Purity: ≥98%
UV/Vis.: λ_{max}: 233, 304 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Fantofarone is supplied as a crystalline solid. A stock solution may be made by dissolving the fantofarone in the solvent of choice, which should be purged with an inert gas. Fantofarone is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of fantofarone in these solvents is approximately 10 mg/ml.

Description

Fantofarone is a calcium channel inhibitor.¹ It selectively inhibits the L-type voltage-gated calcium channel in isolated rat aorta (IC₅₀ = 0.61 nM) over α₁- and β-adrenergic, muscarinic, and histamine H₂ receptors in rat heart homogenates (IC₅₀s = >10, >10, 4, and >10 μM, respectively), and the serotonin receptor subtypes 5-HT₁ and 5-HT₂, as well as histamine H₁ and adenosine A₁ receptors, in rat brain homogenates (IC₅₀s = >10, 4, >10, and >10 μM, respectively). Fantofarone inhibits peak calcium current in depolarized and hyperpolarized L-type voltage-gated calcium channels (IC₅₀s = 1.4 and 150 nM, respectively).² It inhibits potassium chloride- and norepinephrine-induced contractions in isolated rat aorta (IC₅₀s = 5.64 and 96 nM, respectively).¹ It enhances recovery of cardiac output during reperfusion of isolated rat hearts when used at a concentration of 10 nM.³ Fantofarone prevents angioplasty-induced vasospasms in the femoral artery in a rabbit model of focal atherosclerosis when administered at a dose of 50 μg/kg.⁴

References

1. Nokin, P., Clinet, M., Polster, P., *et al.* SR 33557, a novel calcium-antagonist: Interaction with [³H]-(+)-nitrendipine and [³H]-(-)-desmethoxy-verapamil binding sites in cerebral membranes. *Naunyn Schmiedebergs Arch. Pharmacol.* **339(1-2)**, 31-36 (1989).
2. Romey, G., Bois, P., and Lazdunski, M. Effects of two chemically related new Ca²⁺ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. *Eur. J. Pharmacol.* **263(1-2)**, 101-105 (1994).
3. Manning, A., Mouton, J., and Chatelain, P. Fantofarone (SR 33557): Effect on post-ischaemic functional recovery in perfused rat hearts. *Eur. J. Pharmacol.* **220(2-3)**, 249-258 (1992).
4. Dongay, B., Dol-Gleizes, F., and Herbert, J.M. Effect of fantofarone, a new Ca²⁺ channel antagonist, on angioplasty-induced vasospasm in an atherosclerotic rabbit model. *Biochem. Pharmacol.* **55(12)**, 2047-2050 (1998).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/20/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM